0DZ0 Stock Overview
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0DZ0 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
ChemoMetec A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 599.50 |
| 52 Week High | DKK 613.50 |
| 52 Week Low | DKK 282.00 |
| Beta | 1.3 |
| 1 Month Change | 20.67% |
| 3 Month Change | 23.40% |
| 1 Year Change | 30.75% |
| 3 Year Change | -19.23% |
| 5 Year Change | 137.90% |
| Change since IPO | 1,299.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0DZ0 | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 4.7% | -6.9% | -0.9% |
| 1Y | 30.8% | -24.1% | 9.8% |
Return vs Industry: 0DZ0 exceeded the UK Life Sciences industry which returned -24.1% over the past year.
Return vs Market: 0DZ0 exceeded the UK Market which returned 9.8% over the past year.
Price Volatility
| 0DZ0 volatility | |
|---|---|
| 0DZ0 Average Weekly Movement | 5.8% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0DZ0 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0DZ0's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 184 | Martin Behrens | chemometec.com |
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer.
ChemoMetec A/S Fundamentals Summary
| 0DZ0 fundamental statistics | |
|---|---|
| Market cap | DKK 10.43b |
| Earnings (TTM) | DKK 169.08m |
| Revenue (TTM) | DKK 459.54m |
61.7x
P/E Ratio22.7x
P/S RatioIs 0DZ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0DZ0 income statement (TTM) | |
|---|---|
| Revenue | DKK 459.54m |
| Cost of Revenue | DKK 41.04m |
| Gross Profit | DKK 418.51m |
| Other Expenses | DKK 249.43m |
| Earnings | DKK 169.08m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | 9.72 |
| Gross Margin | 91.07% |
| Net Profit Margin | 36.79% |
| Debt/Equity Ratio | 0.2% |
How did 0DZ0 perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield41%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/23 08:44 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ChemoMetec A/S is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kallum Titchmarsh | BofA Global Research |
| null null | Danske Bank |
| Simon Larsson | Danske Bank |